Genetics of Pediatric-Onset Motor Neuron and Neuromuscular Diseases
NCT02532244
Amyotrophic Lateral Sclerosis, Central Nervous System Diseases
Wilmington, Delaware, United States
View Trial DetailsNCT Number: NCT00004568
This study is designed to learn more about the natural history of inherited neurological disorders and the role of heredity in their development. It will examine the genetics, symptoms, disease progression, treatment, and psychological and behavioral impact of diseases in the following categories: hereditary peripheral neuropathies; hereditary myopathies; muscular dystrophies; hereditary motor neuron disorders; mitochondrial myopathies; hereditary neurocognitive disorders; inherited neurological disorders without known diagnosis; and others. Many of these diseases, which affect the brain, spinal cord, muscles, and nerves, are rare and poorly understood.
Children and adults of all ages with various inherited neurological disorders may be eligible for this study. Participants will undergo a detailed medical and family history, and a family tree will be drawn. They will also have a physical and neurological examination that may include blood test and urine tests, an EEG (brain wave recordings), psychological tests, and speech and language and rehabilitation evaluations. A blood sample or skin biopsy may be taken for genetic testing. Depending on the individual patient s symptoms, imaging tests such as X-rays, CT or MRI scans and muscle and nerve testing may also be done.
Information from this study may provide a better understanding of the genetic underpinnings of these disorders, contributing to improved diagnosis, treatment, and genetic counseling, and perhaps leading to additional studies in these areas.
Interested in participating?
Request Info2 year–120 year
All sexes
Observational
University of Mali, Bamako, Mali
The Neurogenetics Branch (NGB) within the National Institute of Neurological Disorders and Stroke (NINDS) is conducting a study to evaluate and provide genetic diagnosis to participants with various diagnosed and undiagnosed neurological conditions.
OBJECTIVES:
The primary objective of this protocol is to provide a resource of participants for enrollment into new research protocols throughout the NGB and other NIH laboratories. Evaluating and diagnosing participants will allow the NGB specialists to maintain their expertise and gain additional knowledge of the course of various neurological disorders. The information obtained will allow for the evaluation and diagnosis of the studied neurological diseases. This understanding may lead to ideas for future protocols. In some cases, blood or other biologic samples (including urine, saliva, or a cheek (buccal) swab) will be obtained for future laboratory studies.
STUDY POPULATION
The number of participants to be enrolled will be set to 3,500 participants with neurological diseases and their unaffected relatives.
DESIGN:
This is an observational diagnostic study of multiple neurological diseases and their pathophysiology.
OUTCOME MEASURES:
No formal outcomes will be measured; however the clinical assessments of enrolled participants can be used to characterize the disease manifestations. In addition, DNA samples obtained may be used to identify and verify causative mutations as well as identify novel genes, which may help establish pathogenic mechanisms and genotype-phenotype correlations.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Participants will be eligible if they:
Exclusion criteria
Participants will not be eligible if they:
-Have a systemic disease that compromises the ability to provide adequate neurologic examination or diagnosis.An example of this would be a contagious disease that would compromise our ability to do an adequate neurological exam.
Time frame: Outcome measures assessed at initial visit and ongoing until a genetic diagnosis is made. Duration of study 15 years (per protocol).
The primary objective of this protocol is to provide a resource of participants for enrollment into new research protocols throughout the NGB and other NIH laboratories. Evaluating and diagnosing participants will allow the NGB specialists to maintain their expertise and gain additional knowledge of the course of various neurological disorders. The information obtained will allow for the evaluation and diagnosis of the studied neurological diseases. This understanding may lead to ideas for future protocols. In some cases, blood or other biologic samples (including urine, saliva, or a cheek (buccal) swab) will be obtained for future laboratory studies. No formal outcomes will be measured; however, the clinical assessments of enrolled participants can be used to characterize the disease manifestations.
Contact information is provided by the study sponsor or research team.
Alice B Schindler
CONTACT
Christopher Grunseich, M.D.
CONTACT
National Institute of Neurological Disorders and Stroke (NINDS)
Nih
Clinical and Molecular Manifestations of Inherited Neurological Disorders
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02532244
Amyotrophic Lateral Sclerosis, Central Nervous System Diseases
Wilmington, Delaware, United States
View Trial DetailsNCT05183152
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Austin, Texas, United States
View Trial DetailsNCT01900132
Inherited Neuromuscular Conditions, Inherited Neuropathies
Bethesda, Maryland, United States
View Trial DetailsNCT07533903
Amyotrophic Lateral Sclerosis, Central Nervous System Diseases
Melbourne, Australia
View Trial Details